SCHEMBL432831

SCHEMBL432831

O=[N+]([O-])c1ccc(C(F)(F)F)nc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.46
ALDH1A1 P00352 3/20 0.46
TSHR P16473 2/20 0.46
CYP3A4 P08684 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
HIF1A Q16665 1/20 0.46
TXNRD1 Q16881 1/20 0.46
TXNRD3 Q86VQ6 1/20 0.46
TXNRD2 Q9NNW7 1/20 0.46
FGFR4 P22455 1/20 0.41
MAPK1 P28482 2/20 0.40
PIN1 Q13526 3/20 0.38
EPAS1 Q99814 1/20 0.37
MAPT P10636 3/20 0.36
JAK2 O60674 1/20 0.36
S1PR4 O95977 1/20 0.36
HSP90AA1 P07900 1/20 0.36
S1PR1 P21453 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29607172 1.00 TDP1 (0.46) TDP1ALDH1A1TSHRCYP3A4HPGD
SCHEMBL18188343 0.81 TSHR (0.41) TDP1ALDH1A1TSHRCYP3A4MAPK1
SCHEMBL8743905 0.79 GPR35 (0.41) TDP1ALDH1A1TSHRCYP3A4HPGD
SCHEMBL31202669 0.79 GPR35 (0.41) TDP1ALDH1A1TSHRCYP3A4HPGD
SCHEMBL898028 0.78 ALDH1A1 (0.42) TDP1ALDH1A1TSHRCYP3A4HPGD
SCHEMBL29745233 0.78 ALDH1A1 (0.42) TDP1ALDH1A1TSHRCYP3A4HPGD
SCHEMBL29004835 0.78 ALDH1A1 (0.39) TDP1ALDH1A1TSHRCYP3A4HPGD
SCHEMBL1749639 0.77 TDP1 (0.44) TDP1ALDH1A1TSHRCYP3A4HPGD
SCHEMBL56616 0.76 MAPT (0.50) TDP1ALDH1A1TSHRTXNRD1FGFR4
SCHEMBL29364858 0.76 MAPT (0.50) TDP1ALDH1A1TSHRTXNRD1FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116574421-B Light heat-insulating paint and preparation method thereof 安徽佐研化学科技有限公司 2024-05-10 CN claimed
CN-116574421-A Light heat-insulating paint and preparation method thereof 安徽佐研化学科技有限公司 2023-08-11 CN claimed
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-01-29 US disclosed
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS RAPPORT THERAPEUTICS, INC. 2025-07-17 US disclosed
EP-3938340-B1 HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS COLLABORATIVE MEDICINAL DEV LLC (US) 2025-07-09 EP disclosed
EP-4558501-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-05-28 EP disclosed
US-12304908-B2 Azabenzimidazoles and their use as AMPA receptor modulators RAPPORT THERAPEUTICS, INC. (US) 2025-05-20 US disclosed
EP-4305033-B1 TRICYCLIC PESTICIDAL COMPOUNDS BASF SE (DE) 2025-05-07 EP disclosed
WO-2025059562-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME ATAVISTIK BIO, INC. (US) 2025-03-20 WO disclosed
WO-2025037871-A1 TRICYCLIC COMPOUND AND USE THEREOF AS MAT2A INHIBITOR 에스케이바이오팜 주식회사 2025-02-20 WO disclosed
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 US disclosed
US-7767687-B2 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors BIOGEN IDEC MA INC. (US) 2010-08-03 US disclosed
US-7767687-B2 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors BIOGEN IDEC MA INC. (US) 2010-08-03 US disclosed
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) 2007-12-20 US disclosed
EP-1787991-A1 PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2007-05-23 EP disclosed
WO-2003086406-A1 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2003-10-23 WO disclosed
WO-2003087099-A1 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2003-10-23 WO disclosed
US-6225320-B1 TREATMENT OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTTHERPETIC NEURALGIA MERCK SHARP & DOHME LTD. (GB) 2001-05-01 US disclosed
EP-0989987-A1 SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2000-04-05 EP disclosed
WO-1998054187-A1 SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 1998-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBL, CBLC TDP1 3145/4885ALDH1A1 3804/4885TSHR 984/4885
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 TDP1 3636/4885ALDH1A1 3684/4885TSHR 4270/4885
US-12304908-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A TDP1 2693/4885ALDH1A1 721/4885TSHR 628/4885
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A TDP1 2817/4885ALDH1A1 765/4885TSHR 651/4885
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use PGA5, ATP6AP1, PPA1 TDP1 4001/4885ALDH1A1 1988/4885TSHR 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.